APO RESEARCH · REPORT
mRNA Cancer Vaccines and Therapeutics
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Product & engineering
Understand the product.
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Selected research
Industry Research
mRNA Cancer Vaccines and Therapeutics Industry Research Report 2026
Market perspective
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
North America is the largest mRNA Cancer Vaccines and Therapeutics market with about 69% market share. Europe is follower, accounting for about 28% market share.
The key players are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology etc. Top 3 companies occupied about 82% market share.
Read the full market overview
Report Scope
This report quantifies the global mRNA Cancer Vaccines and Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to mRNA Cancer Vaccines and Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
mRNA Cancer Vaccines and Therapeutics Market by Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
mRNA Cancer Vaccines and Therapeutics Segment by Type
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas
mRNA Cancer Vaccines and Therapeutics Segment by Application
Infectious Disease
Cancer
Others
mRNA Cancer Vaccines and Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Cancer Vaccines and Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Cancer Vaccines and Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Cancer Vaccines and Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of mRNA Cancer Vaccines and Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Adeno Carcinomas
- Mucinous Carcinomas
- Adenosquamous Carcinomas
Applications
- Infectious Disease
- Cancer
- Others
Companies covered
- Moderna Therapeutics
- CureVac
- Translate Bio
- BioNTech
- Sangamo Therapeutics
- Argos Therapeutics
- In-Cell-Art
- eTheRNA
- Ethris
- Tiba Biotechnology
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 mRNA Cancer Vaccines and Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Adeno Carcinomas
- 2.2.3 Mucinous Carcinomas
- 2.2.4 Adenosquamous Carcinomas
- 2.3 mRNA Cancer Vaccines and Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Infectious Disease
- 2.3.3 Cancer
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 mRNA Cancer Vaccines and Therapeutics Breakdown Data by Type
- 3.1 Global mRNA Cancer Vaccines and Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global mRNA Cancer Vaccines and Therapeutics Forecasted Market Size by Type (2027-2032)
4 mRNA Cancer Vaccines and Therapeutics Breakdown Data by Application
- 4.1 Global mRNA Cancer Vaccines and Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global mRNA Cancer Vaccines and Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global mRNA Cancer Vaccines and Therapeutics Market Perspective (2021-2032)
- 5.2 Global mRNA Cancer Vaccines and Therapeutics Growth Trends by Region
- 5.2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 mRNA Cancer Vaccines and Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 mRNA Cancer Vaccines and Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 mRNA Cancer Vaccines and Therapeutics Market Dynamics
- 5.3.1 mRNA Cancer Vaccines and Therapeutics Industry Trends
- 5.3.2 mRNA Cancer Vaccines and Therapeutics Market Drivers
- 5.3.3 mRNA Cancer Vaccines and Therapeutics Market Challenges
- 5.3.4 mRNA Cancer Vaccines and Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top mRNA Cancer Vaccines and Therapeutics Players by Revenue
- 6.1.1 Global Top mRNA Cancer Vaccines and Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global mRNA Cancer Vaccines and Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of mRNA Cancer Vaccines and Therapeutics Head Office and Area Served
- 6.4 Global mRNA Cancer Vaccines and Therapeutics Players, Product Type & Application
- 6.5 Global mRNA Cancer Vaccines and Therapeutics Manufacturers Established Date
- 6.6 Global mRNA Cancer Vaccines and Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032)
- 7.2 North America mRNA Cancer Vaccines and Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 7.4 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032)
- 8.2 Europe mRNA Cancer Vaccines and Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032)
- 10.2 South America mRNA Cancer Vaccines and Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 10.4 South America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Moderna Therapeutics
- 12.1.1 Moderna Therapeutics Company Information
- 12.1.2 Moderna Therapeutics Business Overview
- 12.1.3 Moderna Therapeutics Revenue in mRNA Cancer Vaccines and Therapeutics Business (2021-2026)
- 12.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 12.1.5 Moderna Therapeutics Recent Developments
- 12.2 CureVac
- 12.2.1 CureVac Company Information
- 12.2.2 CureVac Business Overview
- 12.2.3 CureVac Revenue in mRNA Cancer Vaccines and Therapeutics Business (2021-2026)
- 12.2.4 CureVac mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 12.2.5 CureVac Recent Developments
- 12.3 Translate Bio
- 12.3.1 Translate Bio Company Information
- 12.3.2 Translate Bio Business Overview
- 12.3.3 Translate Bio Revenue in mRNA Cancer Vaccines and Therapeutics Business (2021-2026)
- 12.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 12.3.5 Translate Bio Recent Developments
- 12.4 BioNTech
- 12.4.1 BioNTech Company Information
- 12.4.2 BioNTech Business Overview
- 12.4.3 BioNTech Revenue in mRNA Cancer Vaccines and Therapeutics Business (2021-2026)
- 12.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 12.4.5 BioNTech Recent Developments
- 12.5 Sangamo Therapeutics
- 12.5.1 Sangamo Therapeutics Company Information
- 12.5.2 Sangamo Therapeutics Business Overview
- 12.5.3 Sangamo Therapeutics Revenue in mRNA Cancer Vaccines and Therapeutics Business (2021-2026)
- 12.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 12.5.5 Sangamo Therapeutics Recent Developments
- 12.6 Argos Therapeutics
- 12.6.1 Argos Therapeutics Company Information
- 12.6.2 Argos Therapeutics Business Overview
- 12.6.3 Argos Therapeutics Revenue in mRNA Cancer Vaccines and Therapeutics Business (2021-2026)
- 12.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 12.6.5 Argos Therapeutics Recent Developments
- 12.7 In-Cell-Art
- 12.7.1 In-Cell-Art Company Information
- 12.7.2 In-Cell-Art Business Overview
- 12.7.3 In-Cell-Art Revenue in mRNA Cancer Vaccines and Therapeutics Business (2021-2026)
- 12.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 12.7.5 In-Cell-Art Recent Developments
- 12.8 eTheRNA
- 12.8.1 eTheRNA Company Information
- 12.8.2 eTheRNA Business Overview
- 12.8.3 eTheRNA Revenue in mRNA Cancer Vaccines and Therapeutics Business (2021-2026)
- 12.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 12.8.5 eTheRNA Recent Developments
- 12.9 Ethris
- 12.9.1 Ethris Company Information
- 12.9.2 Ethris Business Overview
- 12.9.3 Ethris Revenue in mRNA Cancer Vaccines and Therapeutics Business (2021-2026)
- 12.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 12.9.5 Ethris Recent Developments
- 12.10 Tiba Biotechnology
- 12.10.1 Tiba Biotechnology Company Information
- 12.10.2 Tiba Biotechnology Business Overview
- 12.10.3 Tiba Biotechnology Revenue in mRNA Cancer Vaccines and Therapeutics Business (2021-2026)
- 12.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 12.10.5 Tiba Biotechnology Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst